Tissue chips to aid drug development and modeling for rare diseases. (1st November 2016)

• Record Type: Journal Article
• Authors: Low, Lucie A.; Tagle, Danilo A.
• Is Part Of: Expert opinion on orphan drugs. Volume 4:Number 11(2016:Nov.)
• Page Start: 1113
• Page End: 1121
• Publication Date: 2016-11-01
• Subjects: Clinical trials -- drug development -- induced pluripotent stem cells (iPSCs) -- microphysiological systems/platforms -- rare diseases -- tissue chips -- toxicity screening; Orphan drugs -- Periodicals; Rare diseases -- Periodicals; Chemotherapy -- Periodicals; 615.1
• DOI: 10.1080/21678707.2016.1244479
• Languages: English
• ISSNs: 2167-8707

Abstract

ABSTRACT: Introduction: The technologies used to design, create and use microphysiological systems (MPS, 'tissue chips' or 'organs-on-chips') have progressed rapidly in the last 5 years, and validation studies of the functional relevance of these platforms to human physiology, and response to drugs for individual model organ systems, are well underway. These studies are paving the way for integrated multi-organ systems that can model diseases and predict drug efficacy and toxicology of multiple organs in real-time, improving the potential for diagnostics and development of novel treatments of rare diseases in the future. Areas covered: This review will briefly summarize the current state of tissue chip research and highlight model systems where these microfabricated (or bioengineered) devices are already being used to screen therapeutics, model disease states, and provide potential treatments in addition to helping elucidate the basic molecular and cellular phenotypes of rare diseases. Expert opinion: Microphysiological systems hold great promise and potential for modeling rare disorders, as well as for their potential use to enhance the predictive power of new drug therapeutics, plus potentially increase the statistical power of clinical trials while removing the inherent risks of these trials in rare disease populations.